Table 2. Determinants of risk of sudden cardiac arrest.
| Outcome | UnadjustedOR (95%CI) | AdjustedOR1 (95%CI) | AdjustedOR2 (95%CI) | AdjustedOR3 (95%CI) |
| Obstructive pulmonary disease | 1.4 (1.2–1.7) | 1.4 (1.1–1.6) | 1.4 (1.1–1.6) | 1.4 (1.2–1.6) |
| High cardiovascular risk-profile4 | 2.5 (2.2–2.9) | 2.3 (2.0–2.7) | 2.3 (2.0–2.7) | 2.5 (2.2–2.9) |
| Diabetes mellitus5 | 1.8 (1.5–2.1) | 1.5 (1.2–1.7) | 1.5 (1.2–1.7) | |
| Use of antiarrhythmic drugs6 | 1.5 (1.1–2.0) | 1.2 (0.9–1.6) | 1.2 (0.9–1.6) | |
| Non-antiarrhythmic QT prolonging drugs class 16 | 1.4 (0.8–2.3) | 1.2 (0.7–2.0) | ||
| Non-antiarrhythmic QT prolonging drugs class 26 | 1.0 (0.7–1.5) | 1.0 (0.7–1.4) |
CI: confidence interval, OR: odds ratio.
1
Adjusted for all potential confounders.
2
Adjusted for all covariates that were univariately associated with sudden cardiac arrest.
3
Adjusted for all covariates that were univariately associated with sudden cardiac arrest and changed the beta with at least 5%.
4
Use of any of the following drugs: β-adrenoreceptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, diuretics, angiotensin-II receptor blockers, nitrates, platelet aggregation inhibitors, and/or statins, within six months prior to index date.
5
Use of anti-diabetics within six months prior to index date.
6
Class I and III antiarrhythmic drugs and non-antiarrhythmic drugs with (possible) risk of QT prolongation. (Table S1).